Mark X. Caddick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mark X. Caddick has a total of 152 co-authors. Here are the top co-authors by number of shared publications:
- Akihiko Kondo
Kobe University
2 shared publications - Arthur F. J. Ram
Institute of Biology Leiden, Leiden University, Sylviusweg 72, 2333 BE Leiden, The Netherlands
2 shared publications - Chenli Liu
Chinese Academy of Sciences
2 shared publications - Chiaki Ogino
Department of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, 1-1 Rokkodai-cho, Nada-ku, Kobe 657-8501, Hyogo, Japan
2 shared publications Chueh Loo Poh
NUS Synthetic Biology for Clinical and Technological Innovation (SynCTI), Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 117456, Singapore
2 shared publications- David Bell
Centre for Synthetic Biology Imperial College London London UK
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 28 October 2021
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 50 (D1) , D898-D911
VEuPathDB: the eukaryotic pathogen, vector and host bioinformatics resource center
The Eukaryotic Pathogen, Vector and Host Informatics Resource (VEuPathDB, https://veupathdb.org) represents the 2019 merger of VectorBase with the EuPathDB projects. As a Bioinformatics Resource Center funded by the National Institutes of Health, with additional support from the Welllcome Trust, VEuPathDB supports >500 organisms comprising invertebrate vectors, eukaryotic pathogens (protists and fungi) and relevant free-living or non-pathogenic species or hosts. Designed to empower researchers with access to Omics data and bioinformatic analyses, VEuPathDB projects integrate >1700 pre-analysed datasets (and associated metadata) with advanced search capabilities, visualizations, and analysis tools in a graphic interface. Diverse data types are analysed with standardized workflows including an in-house OrthoMCL algorithm for predicting orthology. Comparisons are easily made across datasets, data types and organisms in this unique data mining platform. A new site-wide search facilitates access for both experienced and novice users. Upgraded infrastructure and workflows support numerous updates to the web interface, tools, searches and strategies, and Galaxy workspace where users can privately analyse their own data. Forthcoming upgrades include cloud-ready application architecture, expanded support for the Galaxy workspace, tools for interrogating host-pathogen interactions, and improved interactions with affiliated databases (ClinEpiDB, MicrobiomeDB) and other scientific resources, and increased interoperability with the Bacterial & Viral BRC.
- 28 October 2021
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 50 (D1) , D898-D911
Top Cited PapersOpen AccessVEuPathDB: the eukaryotic pathogen, vector and host bioinformatics resource center
The Eukaryotic Pathogen, Vector and Host Informatics Resource (VEuPathDB, https://veupathdb.org) represents the 2019 merger of VectorBase with the EuPathDB projects. As a Bioinformatics Resource Center funded by the National Institutes of Health, with additional support from the Welllcome Trust, VEuPathDB supports >500 organisms comprising invertebrate vectors, eukaryotic pathogens (protists and fungi) and relevant free-living or non-pathogenic species or hosts. Designed to empower researchers with access to Omics data and bioinformatic analyses, VEuPathDB projects integrate >1700 pre-analysed datasets (and associated metadata) with advanced search capabilities, visualizations, and analysis tools in a graphic interface. Diverse data types are analysed with standardized workflows including an in-house OrthoMCL algorithm for predicting orthology. Comparisons are easily made across datasets, data types and organisms in this unique data mining platform. A new site-wide search facilitates access for both experienced and novice users. Upgraded infrastructure and workflows support numerous updates to the web interface, tools, searches and strategies, and Galaxy workspace where users can privately analyse their own data. Forthcoming upgrades include cloud-ready application architecture, expanded support for the Galaxy workspace, tools for interrogating host-pathogen interactions, and improved interactions with affiliated databases (ClinEpiDB, MicrobiomeDB) and other scientific resources, and increased interoperability with the Bacterial & Viral BRC.
- Open Access
- 12 October 2020
- Published by Wiley in Molecular Microbiology
- Vol. 115 (2) , 238-254
Histone mRNA is subject to 3′ uridylation and re‐adenylation in Aspergillus nidulans
The role of post‐transcriptional RNA modification is of growing interest. One example is the addition of non‐templated uridine residues to the 3´ end of transcripts. In mammalian systems uridylation is integral to cell cycle control of histone mRNA levels. This regulatory mechanism is dependent on the nonsense mediated decay (NMD) component, Upf1, which promotes histone mRNA uridylation and degradation in response to the arrest of DNA synthesis. We have identified a similar system in Aspergillus nidulans, where Upf1 is required for the regulation of histone mRNA levels. However, other NMD components are also implicated, distinguishing it from the mammalian system. As in human cells, 3´ uridylation of histone mRNA is induced upon replication arrest. Disruption of this 3´ tagging has a significant but limited effect on histone transcript regulation, consistent with multiple mechanisms acting to regulate mRNA levels. Interestingly, 3´ end degraded transcripts are also subject to re‐adenylation. Both mRNA pyrimidine tagging and re‐adenylation are dependent on the same terminal‐nucleotidyltransferases, CutA and CutB, and we show this is consistent with the in vitro activities of both enzymes. Based on these data we argue that mRNA 3´ tagging has diverse and distinct roles associated with transcript degradation, functionality and regulation.
- 12 October 2020
- Published by Wiley in Molecular Microbiology
- Vol. 115 (2) , 238-254
Open AccessHistone mRNA is subject to 3′ uridylation and re‐adenylation in Aspergillus nidulans
The role of post‐transcriptional RNA modification is of growing interest. One example is the addition of non‐templated uridine residues to the 3´ end of transcripts. In mammalian systems uridylation is integral to cell cycle control of histone mRNA levels. This regulatory mechanism is dependent on the nonsense mediated decay (NMD) component, Upf1, which promotes histone mRNA uridylation and degradation in response to the arrest of DNA synthesis. We have identified a similar system in Aspergillus nidulans, where Upf1 is required for the regulation of histone mRNA levels. However, other NMD components are also implicated, distinguishing it from the mammalian system. As in human cells, 3´ uridylation of histone mRNA is induced upon replication arrest. Disruption of this 3´ tagging has a significant but limited effect on histone transcript regulation, consistent with multiple mechanisms acting to regulate mRNA levels. Interestingly, 3´ end degraded transcripts are also subject to re‐adenylation. Both mRNA pyrimidine tagging and re‐adenylation are dependent on the same terminal‐nucleotidyltransferases, CutA and CutB, and we show this is consistent with the in vitro activities of both enzymes. Based on these data we argue that mRNA 3´ tagging has diverse and distinct roles associated with transcript degradation, functionality and regulation.
- Top Cited PapersOpen Access
- 2 April 2020
- Published by Springer Nature in Fungal Biology and Biotechnology
- Vol. 7 (1) , 1-23
Growing a circular economy with fungal biotechnology: a white paper
Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct opportunities for tackling the urgent challenges before all humans. Fungal biotechnology can advance the transition from our petroleum-based economy into a bio-based circular economy and has the ability to sustainably produce resilient sources of food, feed, chemicals, fuels, textiles, and materials for construction, automotive and transportation industries, for furniture and beyond. Fungal biotechnology offers solutions for securing, stabilizing and enhancing the food supply for a growing human population, while simultaneously lowering greenhouse gas emissions. Fungal biotechnology has, thus, the potential to make a significant contribution to climate change mitigation and meeting the United Nation’s sustainable development goals through the rational improvement of new and established fungal cell factories. The White Paper presented here is the result of the 2nd Think Tank meeting held by the EUROFUNG consortium in Berlin in October 2019. This paper highlights discussions on current opportunities and research challenges in fungal biotechnology and aims to inform scientists, educators, the general public, industrial stakeholders and policymakers about the current fungal biotech revolution.
- 2 April 2020
- Published by Springer Nature in Fungal Biology and Biotechnology
- Vol. 7 (1) , 1-23
Top Cited PapersOpen AccessGrowing a circular economy with fungal biotechnology: a white paper
Fungi have the ability to transform organic materials into a rich and diverse set of useful products and provide distinct opportunities for tackling the urgent challenges before all humans. Fungal biotechnology can advance the transition from our petroleum-based economy into a bio-based circular economy and has the ability to sustainably produce resilient sources of food, feed, chemicals, fuels, textiles, and materials for construction, automotive and transportation industries, for furniture and beyond. Fungal biotechnology offers solutions for securing, stabilizing and enhancing the food supply for a growing human population, while simultaneously lowering greenhouse gas emissions. Fungal biotechnology has, thus, the potential to make a significant contribution to climate change mitigation and meeting the United Nation’s sustainable development goals through the rational improvement of new and established fungal cell factories. The White Paper presented here is the result of the 2nd Think Tank meeting held by the EUROFUNG consortium in Berlin in October 2019. This paper highlights discussions on current opportunities and research challenges in fungal biotechnology and aims to inform scientists, educators, the general public, industrial stakeholders and policymakers about the current fungal biotech revolution.
- Open Access
- 17 October 2019
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 8 (42) , e00479-19
High-Quality Draft Genome Sequence and Annotation of the Basidiomycete Yeast Sporisorium graminicola CBS10092, a Producer of Mannosylerythritol Lipids
The basidiomycete Sporisorium graminicola (formally Pseudozyma graminicola ) strain CBS10092 was originally isolated from an herbaceous plant in Russia. It is a known producer of mannosylerythritol lipids (MELs), the main component being MEL-C. Here, we present the 19.9-Mb draft genome sequence, which comprises 6,602 genes, including those encoding the MEL biosynthetic pathway.
- 17 October 2019
- Published by American Society for Microbiology in Microbiology Resource Announcements
- Vol. 8 (42) , e00479-19
Open AccessHigh-Quality Draft Genome Sequence and Annotation of the Basidiomycete Yeast Sporisorium graminicola CBS10092, a Producer of Mannosylerythritol Lipids
The basidiomycete Sporisorium graminicola (formally Pseudozyma graminicola ) strain CBS10092 was originally isolated from an herbaceous plant in Russia. It is a known producer of mannosylerythritol lipids (MELs), the main component being MEL-C. Here, we present the 19.9-Mb draft genome sequence, which comprises 6,602 genes, including those encoding the MEL biosynthetic pathway.
- Open Access
- 11 July 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-2
Author Correction: Building a global alliance of biofoundries
The original version of this Comment contained errors in the legend of Figure 2, in which the locations of the fifteenth and sixteenth GBA members were incorrectly given as ‘(15) Australian Genome Foundry, Macquarie University; (16) Australian Foundry for Advanced Biomanufacturing, University of Queensland.’. The correct version replaces this with ‘(15) Australian Foundry for Advanced Biomanufacturing (AusFAB), University of Queensland and (16) Australian Genome Foundry, Macquarie University’. This has been corrected in both the PDF and HTML versions of the Comment.
- 11 July 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-2
Open AccessAuthor Correction: Building a global alliance of biofoundries
The original version of this Comment contained errors in the legend of Figure 2, in which the locations of the fifteenth and sixteenth GBA members were incorrectly given as ‘(15) Australian Genome Foundry, Macquarie University; (16) Australian Foundry for Advanced Biomanufacturing, University of Queensland.’. The correct version replaces this with ‘(15) Australian Foundry for Advanced Biomanufacturing (AusFAB), University of Queensland and (16) Australian Genome Foundry, Macquarie University’. This has been corrected in both the PDF and HTML versions of the Comment.
- Top Cited PapersOpen Access
- 9 May 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-4
Building a global alliance of biofoundries
Biofoundries provide an integrated infrastructure to enable the rapid design, construction, and testing of genetically reprogrammed organisms for biotechnology applications and research. Many biofoundries are being built and a Global Biofoundry Alliance has recently been established to coordinate activities worldwide.
- 9 May 2019
- Published by Springer Nature in Nature Communications
- Vol. 10 (1) , 1-4
Top Cited PapersOpen AccessBuilding a global alliance of biofoundries
Biofoundries provide an integrated infrastructure to enable the rapid design, construction, and testing of genetically reprogrammed organisms for biotechnology applications and research. Many biofoundries are being built and a Global Biofoundry Alliance has recently been established to coordinate activities worldwide.
- Top Cited PapersOpen Access
- 31 August 2016
- Published by Springer Nature in Fungal Biology and Biotechnology
- Vol. 3 (1) , 1-17
Current challenges of research on filamentous fungi in relation to human welfare and a sustainable bio-economy: a white paper
The EUROFUNG network is a virtual centre of multidisciplinary expertise in the field of fungal biotechnology. The first academic-industry Think Tank was hosted by EUROFUNG to summarise the state of the art and future challenges in fungal biology and biotechnology in the coming decade. Currently, fungal cell factories are important for bulk manufacturing of organic acids, proteins, enzymes, secondary metabolites and active pharmaceutical ingredients in white and red biotechnology. In contrast, fungal pathogens of humans kill more people than malaria or tuberculosis. Fungi are significantly impacting on global food security, damaging global crop production, causing disease in domesticated animals, and spoiling an estimated 10 % of harvested crops. A number of challenges now need to be addressed to improve our strategies to control fungal pathogenicity and to optimise the use of fungi as sources for novel compounds and as cell factories for large scale manufacture of bio-based products. This white paper reports on the discussions of the Think Tank meeting and the suggestions made for moving fungal bio(techno)logy forward.
- 31 August 2016
- Published by Springer Nature in Fungal Biology and Biotechnology
- Vol. 3 (1) , 1-17
Top Cited PapersOpen AccessCurrent challenges of research on filamentous fungi in relation to human welfare and a sustainable bio-economy: a white paper
The EUROFUNG network is a virtual centre of multidisciplinary expertise in the field of fungal biotechnology. The first academic-industry Think Tank was hosted by EUROFUNG to summarise the state of the art and future challenges in fungal biology and biotechnology in the coming decade. Currently, fungal cell factories are important for bulk manufacturing of organic acids, proteins, enzymes, secondary metabolites and active pharmaceutical ingredients in white and red biotechnology. In contrast, fungal pathogens of humans kill more people than malaria or tuberculosis. Fungi are significantly impacting on global food security, damaging global crop production, causing disease in domesticated animals, and spoiling an estimated 10 % of harvested crops. A number of challenges now need to be addressed to improve our strategies to control fungal pathogenicity and to optimise the use of fungi as sources for novel compounds and as cell factories for large scale manufacture of bio-based products. This white paper reports on the discussions of the Think Tank meeting and the suggestions made for moving fungal bio(techno)logy forward.
- 1 April 2004
- Published by Elsevier in Trends in Plant Science
- Vol. 9 (4) , 159-161
Ethanol-inducible gene expression: first step towards a new green revolution?
- 1 April 2004
- Published by Elsevier in Trends in Plant Science
- Vol. 9 (4) , 159-161
Ethanol-inducible gene expression: first step towards a new green revolution?